AIM Ondine Biomedical - Capital Access Window - Ondine Biomedical Inc
RNS Number : 6650ZAIM20 October 2026NOTICE
20/10/2026 7:30am
RESTORATION OF TRADING ON AIM
ONDINE BIOMEDICAL INC
Trading on AIM for the under-mentioned securities was temporarily suspended, pursuant to a Capital Access Window. The Capital Access Window has closed and trading restored from 20/10/2026 7:30am, an announcement having been made.
COMMON SHARES OF NO PAR VALUE, FULLY PAID (CDI)
(BNZGQK5) (CA68234M2058)
If you have any queries relating to the above, please contact the Company's nominated adviser on +44 (0)20 7409 3494.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDEXCPPGMUUUPQUQU
Recent news on Ondine Biomedical
See all newsAIM Ondine Biomedical - Capital Access Window - Ondine Biomedical Inc
Brief: Ondine Biomedical Confirms Total Gross Proceeds From Placing And Subscription Are £10 Million
Ondine Biomedical - Result of Fundraise, Restoration of Trading & TVR
Brief: Ondine Biomedical Announces A Proposed Fundraising Of About £10 Mln
Ondine Biomedical - Proposed c.£10m (C$18.88m) Fundraise